Experimental drug aims to reverse liver damage in rare triple condition
Disease control
Recruiting now
This study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.
Phase 2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC